Severe adverse reactions with contrast agents for magnetic resonance: clinical experience in 30,000 MR examinations

Area of Science:

• Radiology
• Medical Imaging
• Pharmacology

Background:

• Magnetic Resonance (MR) imaging utilizes contrast media to enhance diagnostic accuracy.
• Gadolinium-based contrast agents (GBCAs) are commonly administered intravenously for MRI examinations.
• Assessing the safety profile of GBCAs is crucial for clinical practice.

Observation:

• A retrospective analysis was conducted on 30,000 patients receiving gadolinium contrast media (gadoterate meglumine or gadopentetate dimeglumine) between 1988 and 1998.
• Adverse events were systematically recorded and categorized as mild, moderate, or severe.
• Institutional data collection focused on reactions following intravenous GBCA administration during MRI.

Findings:

• The study identified a low incidence of adverse reactions to gadolinium contrast media.
• Over the 10-year study period, only three reports of moderate or severe reactions were documented.
• The frequency and manifestations of reactions to specific GBCAs were evaluated.

Implications:

• Intravenous gadolinium contrast media demonstrate a favorable safety profile in a large patient cohort.
• This data supports the continued use of gadoterate meglumine and gadopentetate dimeglumine in clinical MR imaging.
• Understanding GBCA safety is essential for radiologists and referring physicians.